Fonder MA, Cummins DL, Ehst BD, Anhalt GJ, Meyerle JH, et al.
Journal of burns and wounds. Date of publication 2006 Nov 20;volume 5():e8.
1. J Burns Wounds. 2006 Nov 20;5:e8.
Adalimumab therapy for recalcitrant pyoderma gangrenosum.
Fonder MA(1), Cummins DL, Ehst BD, Anhalt GJ, Meyerle JH.
Author information:
(1)Department of Dermatology, Johns Hopkins Medical Institutions, Baltimore, MD,
USA.
OBJECTIVE: To describe a patient with treatment-refractory pyoderma gangrenosum
and the outcome of a novel therapeutic approach.
METHODS: Case report and review of the literature.
RESULTS: A patient with inflammatory bowel disease developed severe pyoderma
gangrenosum while receiving treatment with the chimeric anti-TNF-alpha antibody
infliximab. Despite subsequent trials of numerous immunosuppressive and
immunomodulatory medications, the dermatologic disease progressed. The patient's
ulcers finally resolved when treatment with adalimumab, a fully humanized
monoclonal antibody specific for TNF-alpha, was initiated.
CONCLUSIONS: We report a novel application of the TNF-alpha inhibitor,
adalimumab, in the treatment of pyoderma gangrenosum.
PMCID: PMC1687150
PMID: 17149453
